Chair, Department of Leukemia, Samsung Distinguished University Chair in Cancer Medicine, Associate Vice President for Global Academic Programs - The University of Texas MD Anderson Cancer Center, Houston, Texas
Oncology
Dr. Hagop M. Kantarjian, MD
|
|
Give Review
Hagop Kantarjian is an expert in the field of Oncology. He received awards:"America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer", "Super Doctor", "Lifetime Achievement Award", "National Physician of the Year Award for Lifetime Achievement", "President's Recognition", "Regents' Outstanding Teaching Award", "Waun Ki Hong Award for Excellence in Team Science", "Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer", "Giants of Cancer Care Award", "Medal in Health Care Excellence", "Thomson Reuters Highly Cited Researcher", "Joseph H. Burchenal Memorial Award", "Charles Koller, MD Lectureship Award", "37th Jeffrey A Gottlieb Memorial Award", "Grinberg-Wisch Lecture Award", "Distinguished Lecturer Award", "Top 1% of Physicians", "WAAAUB Distinguished Alumni Award", "Robert A. Kyle Award for Outstanding Clinician Scientist", "Ben Qurrah Award", "Best Doctors in America", "Best Doctors", "John Mendelsohn Lifetime Scientific Achievement Award", "Schwartz Lecturship Award", "AUB Medical Alumni Gold Metal Award", "Faculty Achievement Award for Clinical Research", "Gold Medal Award", "First Emil J Freireich Award for Outstanding Clinical Research", "Outstanding Service to Mankind Award", "Scholar", "Fellow Research Award", "Alpha Omega Alpha Honor Medical Society", "Penrose Award" and "Lange Award". Hagop Kantarjian is a published physician as well. He has 103 publications published. The latest was: Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. He is registered with Medicare.
Publications
- Rigosertib versus best supportive care for patients with high-risk Myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled,...
- Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.
- Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal ...
- Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in Acute myeloid leukemia.
- Outcomes of patients with myelodysplastic syndromes who achieve stable Disease after treatment with hypomethylating agents.
- Clinical implications of TP53 mutations in Myelodysplastic syndromes treated with hypomethylating agents.
- Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous Leukemia in the era of tyrosine kinase inhibitor ...
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid Leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
- Analysis of 2013 European LeukaemiaNet (ELN) responses in Chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
- A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed Acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Outcomes for patients with chronic lymphocytic leukemia and Acute leukemia or myelodysplastic syndrome.
- Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
- Pre-BCR signaling in precursor B-cell Acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1, and MYC, and can be targeted by SYK inhibition.
- Role of inotuzumab ozogamicin in the treatment of relapsed/refractory Acute lymphoblastic leukemia.
- Chronic myeloid Leukemia: 2016 update on diagnosis, therapy, and monitoring.
- Interactions and relevance of blast percentage and treatment strategy among younger and older patients with Acute myeloid leukemia (AML) and myelodysplastic syndrome (...
- Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).
- Value of the 340B Drug Discount Program.
- Tamibarotene in patients with Acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
- The Hippocratic Oath, the US Health Care System, and the Affordable Care Act in 2015.
- Reply to price and value in Cancer care.
- Factors influencing long-term efficacy and tolerability of bosutinib in Chronic phase Chronic myeloid leukaemia resistant or intolerant to imatinib.
- Improvement in clinical outcome of FLT3 ITD mutated Acute myeloid leukemia patients over the last one and a half decade.
- Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive Acute lymphoblastic leukaemia: a single-centre, phase...
- Nilotinib in patients with systemic Mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study.
- Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
- Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with Acute lymphoblastic leukaemia.
- Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic Leukemia.
- Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory Acute myeloid leukaemia (VALOR): a randomised, controlled, doubl...
- IDH1 and IDH2 mutations in myelodysplastic syndromes and role in Disease progression.
- Estimated glomerular filtration rate changes in patients with chronic myeloid Leukemia treated with tyrosine kinase inhibitors.
- Increased likelihood of post-Polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.
- Inotuzumab ozogamicin in B-cell Acute lymphoblastic leukemias and non-Hodgkin's lymphomas.
- The role of ponatinib in Philadelphia chromosome-positive Acute lymphoblastic leukemia.
- Myelopathy following intrathecal chemotherapy in adults: a single institution experience.
- Single-Cell mass cytometry reveals intraCellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor Cells.
- Outcomes of patients with chronic lymphocytic Leukemia after discontinuing ibrutinib.
- Clonal evolution of Acute myeloid leukemia relapsed after 19 years of remission.
- Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-Cell Malignancies.
- Targeting interleukin-11 receptor in Leukemia and lymphoma: A functional ligand-directed study and hematopathology analysis of patient-derived specimens.
- Secondary Mutations as Mediators of Resistance to Targeted Therapy in Leukemia.
- Mutational profiling of therapy-related myelodysplastic syndromes and Acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
- A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes.
- Prognostic factors for outcome in patients with refractory and relapsed Acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.
- Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed Acute myeloid leukemia.
- Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in Acute myeloid ...
- A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia.
- Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.
- High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic Leukemia is an independent predictor of adverse outcome.
- Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed Acute myeloid leukemia and Acute lymphoblastic leukemia.
- Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis.
- Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid Leukemia: Results with 24 months ...
- Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation.
- Effectiveness of Homoharringtonine (Omacetaxine Mepesuccinate) for Treatment of Acute Myeloid Leukemia: A Meta-Analysis of Chinese Studies.
- RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with Acute myeloid leukaemia inv(16) subtype.
- Three-year efficacy, oVerall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study.
- Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia.
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor Acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
- Multiple myeloma and Chronic leukaemias in 2014: Improved understanding of disease biology and treatment.
- Comprehensive craniospinal radiation for controlling central nervous system Leukemia.
- The effect of calcium channel blockers on the outcome of Acute myeloid leukemia.
- Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with Acute myeloid leukemia and myelodysplastic syndrome.
- A retrospective study of venous thromboembolism in Acute leukemia patients treated at the University of Texas MD Anderson Cancer Center.
- A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.
- Outcome of patients with low-risk and intermediate-1-risk Myelodysplastic syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research...
- Incidence of secondary neoplasms in patients with Acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid p...
- Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in Acute promyelocytic leukaemia.
- Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory Acute lymphocytic leukaemia.
- Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced Cell death through BIRC2/MAP3K14 signa...
- Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory Acute lymphoblastic leukemia.
- Life After FCR: Outcomes of patients with chronic lymphocytic Leukemia who progress after frontline treatment with Fludarabine, Cyclophosphamide and Rituximab.
- Clinical characteristics and outcomes in patients with Acute promyelocytic leukaemia and hyperleucocytosis.
- Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and Acute myelogenous leukemia.
- Safety and activity of ibrutinib plus rituximab for patients with high-risk Chronic lymphocytic leukaemia: a single-arm, phase 2 study.
- Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal Myelodysplastic syndromes.
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia.
- Progress in Acute Myeloid Leukemia.
- A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
- Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
- Ruxolitinib and survival improvement in patients with myelofibrosis.
- Chemotherapy drug shortages in the United States revisited.
- TET2 mutations predict response to hypomethylating agents in Myelodysplastic syndrome patients.
- Improving Outcomes for Patients with Acute Myeloid Leukemia in First Relapse: A Single Center Experience.
- Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant Anemia.
- The proceedings of the initial meeting of the society of hematologic oncology 2013.
- Clinical significance of microcytosis in patients with primary myelofibrosis.
- Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk Myelodysplastic syndromes.
- Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with Acute lymphoblastic leukemia (ALL).
- Complete Cytogenetic Response, Not Deep Molecular Response, Is Associated With Survival in Chronic Myeloid Leukemia.
- Reply to J.S. Abrams et al.
- FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic Leukemia.
- Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acut...
- The effect of decitabine dose modification and myelosuppression on response and survival in patients with Myelodysplastic syndromes.
- Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of Acute myeloid leukemia.
- Sox4/Tcf7l1 axis promotes progression of BCR- ABL+ Acute lymphoblastic leukemia.
- Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid Leukemia.
- Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?
- SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic Cells and stem Cells in advanced phase chronic myeloid...
- Kinetics of chronic lymphocytic Leukemia (CLL) cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
- Chronic myeloid Leukemia: 2014 update on diagnosis, monitoring, and management.
- Risk stratification of chromosomal abnormalities in chronic myelogenous Leukemia in the era of tyrosine kinase inhibitor therapy.
- Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory Myeloid malignancies.
Schools
American University of Beirut Faculty of Medicine
Am University Beirut
MD Anderson Cancer Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Super Doctor
- Lifetime Achievement Award
- National Physician of the Year Award for Lifetime Achievement
- President's Recognition
- Regents' Outstanding Teaching Award
- Waun Ki Hong Award for Excellence in Team Science
- Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer
- Giants of Cancer Care Award
- Medal in Health Care Excellence
- Thomson Reuters Highly Cited Researcher
- Joseph H. Burchenal Memorial Award
- Charles Koller, MD Lectureship Award
- 37th Jeffrey A Gottlieb Memorial Award
- Grinberg-Wisch Lecture Award
- Distinguished Lecturer Award
- Top 1% of Physicians
- WAAAUB Distinguished Alumni Award
- Robert A. Kyle Award for Outstanding Clinician Scientist
- Ben Qurrah Award
- Best Doctors in America
- Best Doctors
- John Mendelsohn Lifetime Scientific Achievement Award
- Schwartz Lecturship Award
- AUB Medical Alumni Gold Metal Award
- Faculty Achievement Award for Clinical Research
- Gold Medal Award
- First Emil J Freireich Award for Outstanding Clinical Research
- Outstanding Service to Mankind Award
- Scholar
- Fellow Research Award
- Alpha Omega Alpha Honor Medical Society
- Penrose Award
- Lange Award
Education
-
University of Texas MD Anderson Cancer Center -
American University of Beirut Faculty of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1316020290 | |
| NPPES Provider LastName | KANTARJIAN | |
| NPPES Provider FirstName | HAGOP | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 902.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1316020290 |
| Last Name Of The Provider | KANTARJIAN |
| First Name Of The Provider | HAGOP |
| View All |
Similar Doctors
|
|
Dr. Jean-Pierre Ayoub, MD |
|
|
Dr. Shagufta N. Naqvi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher J. Logothetis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nizar M. Tannir, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jay B. Shah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kimberly H. Koenig, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John Thachil, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erminia Massarelli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sao Jiralerspong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel E. Epner II, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ken H. Young, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pierre Saintigny, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Elnora Y. Baker |